Eigentler, Thomas K.

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

Gutzmer, R., Stroyakovskiy, D., Gogas, H., Robert, C., Lewis, K., Protsenko, S., Pereira, R. P., Eigentler, T., Rutkowski, P., Demidov, L., et al. (2020) · The Lancet

Melanoma and MAPK PathwaysCancer Immunotherapy and Biomarkers

Cited by 663

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

Martens, A., Wistuba-Hamprecht, K., Foppen, M. G., Yuan, J., Postow, M. A., Wong, P., Romano, E., Khammari, A., Dreno, B., Capone, M., et al. (2016) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 541

Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb/IV CheckMate 511 trial

Lebbé, C., Meyer, N., Mortier, L., Marquez-Rodas, I., Robert, C., Rutkowski, P., Menzies, A. M., Eigentler, T., Ascierto, P. A., Smylie, M., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 408

Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients

Weide, B., Pascolo, S., Scheel, B., Derhovanessian, E., Pflugfelder, A., Eigentler, T. K., Pawelec, G., Hoerr, I., Rammensee, H.-G., & Garbe, C. (2009) · Journal of Immunotherapy

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 378

Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA

Weide, B., Carralot, J.-P., Reese, A., Scheel, B., Eigentler, T. K., Hoerr, I., Rammensee, H.-G., Garbe, C., & Pascolo, S. (2008) · Journal of Immunotherapy

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 261

Effectiveness and Tolerability of Ipilimumab: Experiences From 198 Patients Included in a Named-Patient Program in Various Daily-Practice Settings and Multiple Institutions

Eigentler, T. K., Schlaak, M., Hassel, J. C., Loquai, C., Stoffels, I., Gutzmer, R., Pätzold, S., Mohr, P., Keller, U., Starz, H., et al. (2014) · Journal of Immunotherapy

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 23